AbbVie vs. Pfizer: A Financial Comparison
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy ABBV?
Source: Fool
- Patent Management Advantage: AbbVie has effectively managed its patent portfolio with 130 patents surrounding its immunology therapy Humira, which was the world's best-selling drug for six consecutive years, while Pfizer's Comirnaty took the lead during the pandemic, AbbVie's drug lineup shows greater market resilience.
- Sales Growth Potential: AbbVie's Skyrizi and Rinvoq are projected to generate $17.6 billion and $8.3 billion in sales in 2025, respectively, totaling $25.9 billion, which significantly surpasses Humira's $21.2 billion in 2022, highlighting the diversification and profitability of its product portfolio.
- Dividend Safety: While Pfizer boasts a dividend yield of 6.3%, its payout ratio of 107% indicates unsustainability, whereas AbbVie offers a 3.2% yield with a more manageable payout ratio of 65%, suggesting a more stable dividend payment structure.
- Financial Growth Outlook: AbbVie expects to achieve revenue of around $67 billion in 2026, reflecting a 9.5% increase, while Pfizer's revenue is projected to decline by 2.5%, showcasing AbbVie's clear advantage in financial growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 197.380
Low
223.00
Averages
252.00
High
289.00
Current: 197.380
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Submits New Drug Application for Alopecia Treatment
- Clinical Trial Success: In the Phase 3 UP-AA clinical program, upadacitinib achieved the primary endpoint of a SALT score ≤ 20 at week 24, demonstrating significant efficacy that could potentially improve patients' quality of life and reshape treatment paradigms for severe alopecia areata.
- Hair Regrowth Breakthrough: Upadacitinib is the first JAK inhibitor to meet the ranked secondary endpoint of complete scalp hair regrowth (SALT = 0) at week 24, showcasing its unique advantages in treating alopecia, which may attract a larger patient base.
- Broad Patient Population: Approximately 51% of the 716 patients in the trial had a baseline SALT score ≥ 95, indicating near-total scalp hair loss, and the efficacy results of upadacitinib provide new hope for these patients, potentially driving significant market demand.
- Regulatory Review Underway: The safety and efficacy of upadacitinib are currently under regulatory review by the U.S. FDA and the European Medicines Agency, and if approved, it will open new market opportunities for AbbVie in the immunotherapy sector, further solidifying its industry position.
See More
AbbVie’s Rinvoq Outperforms Humira in Rheumatoid Arthritis Study
- Clinical Trial Success: AbbVie’s SELECT-SWITCH study demonstrated that Rinvoq outperformed Humira in treating adults with moderate to severe rheumatoid arthritis, successfully meeting its primary endpoint and showcasing significant superiority in achieving low disease activity.
- Efficacy Comparison Data: Approximately 43.3% of patients treated with Rinvoq achieved low disease activity compared to only 22.4% for Humira, indicating a clear competitive advantage for Rinvoq in terms of treatment efficacy.
- Safety Assessment: Both treatments showed no new safety concerns during the 12-week study period, further enhancing Rinvoq's market acceptance and patient confidence in its use.
- Positive Market Reaction: AbbVie shares rose over 1% in pre-market trading on Tuesday, reflecting investor optimism regarding the study results, which may drive further growth for the company in the rheumatoid arthritis market.
See More
AbbVie Seeks FDA Approval for Subcutaneous Skyrizi
- FDA Application Filed: AbbVie has submitted an application to the US FDA for approval of a subcutaneous formulation of Skyrizi (risankizumab), aiming to provide a more convenient administration method that is expected to enhance patient adherence.
- Clinical Trial Support: The application is backed by data from the phase 3 AFFIRM trial, which enrolled patients with moderately to severely active Crohn's disease, demonstrating significant clinical efficacy.
- Efficacy Metrics Achieved: At week 12, Skyrizi surpassed placebo on both co-primary endpoints, Crohn's Disease Activity Index (CDAI) clinical remission and endoscopic response, indicating its substantial therapeutic effect.
- Expected Approval Timeline: AbbVie anticipates receiving approval for subcutaneous Skyrizi by the end of the year, which will further bolster the company's competitive position in the Crohn's disease treatment market.
See More
AbbVie Seeks FDA Approval for SKYRIZI Induction Regimen
- New Treatment Application: AbbVie has submitted an application to the U.S. FDA for a subcutaneous induction regimen of SKYRIZI, aimed at providing a new treatment option for adults with moderately to severely active Crohn's disease, showcasing the company's ongoing innovation in gastrointestinal disorders.
- Clinical Trial Support: The application is backed by positive Phase 3 AFFIRM study results, which evaluated the efficacy and safety of SKYRIZI as an induction treatment, particularly in patients with prior advanced therapy failure, indicating strong potential market demand for the drug.
- Market Outlook: SKYRIZI was first approved for Crohn's disease in 2022, and AbbVie expects a decision on the new dosing regimen later this year, which could further solidify its position in the biopharmaceutical market.
- Stock Price Dynamics: Although AbbVie shares closed at $198.71 on Friday, down 1.11%, the new treatment application may positively impact future stock performance, reflecting market expectations for its innovative therapies.
See More
Chaos Erupts at White House Correspondents' Dinner Amid Security Incident
- White House Chaos: An armed man charged a security checkpoint during the White House Correspondents' Dinner, prompting evacuation of President Trump and officials, which has drawn widespread condemnation and highlights increasing political violence in the U.S.
- Investigation Closure: The Justice Department has ended its criminal investigation into Fed Chair Jerome Powell, clearing the way for Trump's nominee Kevin Warsh, which could significantly influence future monetary policy decisions.
- Iran Negotiation Halt: Trump canceled plans to send U.S. representatives to Pakistan for ceasefire talks, resulting in Brent crude prices surpassing $106 per barrel, exerting downward pressure on stock futures amid faltering peace talks.
- Tesla AI Testing: Tesla is beta testing xAI's Grok chatbot for in-vehicle voice commands, aiming to enhance driver experience, but safety experts warn that such features could distract drivers and compromise road safety.
See More
AbbVie Submits SKYRIZI Application for Crohn's Disease Treatment
- FDA Application Submitted: AbbVie has submitted an application to the U.S. FDA for SKYRIZI (risankizumab-rzaa) for subcutaneous induction treatment of moderately to severely active Crohn's disease, with anticipated approval later this year, which would provide new treatment options and enhance patient quality of life.
- Clinical Trial Support: The application is backed by positive data from the Phase 3 AFFIRM study, which demonstrated the efficacy and safety of risankizumab in adult patients with moderately to severely active Crohn's disease, involving 289 patients, of whom 65% had previously failed advanced therapies, indicating significant market demand for the drug.
- Diverse Treatment Options: If approved, patients will have the choice to receive SKYRIZI induction via subcutaneous injection or IV infusion, followed by subcutaneous maintenance dosing every eight weeks, which will likely improve patient adherence and treatment outcomes due to increased flexibility.
- Broad Impact of Crohn's Disease: Crohn's disease affects approximately 1 million Americans, causing significant physical and emotional burdens; AbbVie is committed to enhancing treatment standards through innovative research, reflecting the company's ongoing investment and dedication in the field of immunology.
See More
AbbVie Submits New Drug Application for Alopecia Treatment
- Clinical Trial Success: In the Phase 3 UP-AA clinical program, upadacitinib achieved the primary endpoint of a SALT score ≤ 20 at week 24, demonstrating significant efficacy that could potentially improve patients' quality of life and reshape treatment paradigms for severe alopecia areata.
- Hair Regrowth Breakthrough: Upadacitinib is the first JAK inhibitor to meet the ranked secondary endpoint of complete scalp hair regrowth (SALT = 0) at week 24, showcasing its unique advantages in treating alopecia, which may attract a larger patient base.
- Broad Patient Population: Approximately 51% of the 716 patients in the trial had a baseline SALT score ≥ 95, indicating near-total scalp hair loss, and the efficacy results of upadacitinib provide new hope for these patients, potentially driving significant market demand.
- Regulatory Review Underway: The safety and efficacy of upadacitinib are currently under regulatory review by the U.S. FDA and the European Medicines Agency, and if approved, it will open new market opportunities for AbbVie in the immunotherapy sector, further solidifying its industry position.
See More
AbbVie’s Rinvoq Outperforms Humira in Rheumatoid Arthritis Study
- Clinical Trial Success: AbbVie’s SELECT-SWITCH study demonstrated that Rinvoq outperformed Humira in treating adults with moderate to severe rheumatoid arthritis, successfully meeting its primary endpoint and showcasing significant superiority in achieving low disease activity.
- Efficacy Comparison Data: Approximately 43.3% of patients treated with Rinvoq achieved low disease activity compared to only 22.4% for Humira, indicating a clear competitive advantage for Rinvoq in terms of treatment efficacy.
- Safety Assessment: Both treatments showed no new safety concerns during the 12-week study period, further enhancing Rinvoq's market acceptance and patient confidence in its use.
- Positive Market Reaction: AbbVie shares rose over 1% in pre-market trading on Tuesday, reflecting investor optimism regarding the study results, which may drive further growth for the company in the rheumatoid arthritis market.
See More
AbbVie Seeks FDA Approval for Subcutaneous Skyrizi
- FDA Application Filed: AbbVie has submitted an application to the US FDA for approval of a subcutaneous formulation of Skyrizi (risankizumab), aiming to provide a more convenient administration method that is expected to enhance patient adherence.
- Clinical Trial Support: The application is backed by data from the phase 3 AFFIRM trial, which enrolled patients with moderately to severely active Crohn's disease, demonstrating significant clinical efficacy.
- Efficacy Metrics Achieved: At week 12, Skyrizi surpassed placebo on both co-primary endpoints, Crohn's Disease Activity Index (CDAI) clinical remission and endoscopic response, indicating its substantial therapeutic effect.
- Expected Approval Timeline: AbbVie anticipates receiving approval for subcutaneous Skyrizi by the end of the year, which will further bolster the company's competitive position in the Crohn's disease treatment market.
See More
AbbVie Seeks FDA Approval for SKYRIZI Induction Regimen
- New Treatment Application: AbbVie has submitted an application to the U.S. FDA for a subcutaneous induction regimen of SKYRIZI, aimed at providing a new treatment option for adults with moderately to severely active Crohn's disease, showcasing the company's ongoing innovation in gastrointestinal disorders.
- Clinical Trial Support: The application is backed by positive Phase 3 AFFIRM study results, which evaluated the efficacy and safety of SKYRIZI as an induction treatment, particularly in patients with prior advanced therapy failure, indicating strong potential market demand for the drug.
- Market Outlook: SKYRIZI was first approved for Crohn's disease in 2022, and AbbVie expects a decision on the new dosing regimen later this year, which could further solidify its position in the biopharmaceutical market.
- Stock Price Dynamics: Although AbbVie shares closed at $198.71 on Friday, down 1.11%, the new treatment application may positively impact future stock performance, reflecting market expectations for its innovative therapies.
See More
Chaos Erupts at White House Correspondents' Dinner Amid Security Incident
- White House Chaos: An armed man charged a security checkpoint during the White House Correspondents' Dinner, prompting evacuation of President Trump and officials, which has drawn widespread condemnation and highlights increasing political violence in the U.S.
- Investigation Closure: The Justice Department has ended its criminal investigation into Fed Chair Jerome Powell, clearing the way for Trump's nominee Kevin Warsh, which could significantly influence future monetary policy decisions.
- Iran Negotiation Halt: Trump canceled plans to send U.S. representatives to Pakistan for ceasefire talks, resulting in Brent crude prices surpassing $106 per barrel, exerting downward pressure on stock futures amid faltering peace talks.
- Tesla AI Testing: Tesla is beta testing xAI's Grok chatbot for in-vehicle voice commands, aiming to enhance driver experience, but safety experts warn that such features could distract drivers and compromise road safety.
See More
AbbVie Submits SKYRIZI Application for Crohn's Disease Treatment
- FDA Application Submitted: AbbVie has submitted an application to the U.S. FDA for SKYRIZI (risankizumab-rzaa) for subcutaneous induction treatment of moderately to severely active Crohn's disease, with anticipated approval later this year, which would provide new treatment options and enhance patient quality of life.
- Clinical Trial Support: The application is backed by positive data from the Phase 3 AFFIRM study, which demonstrated the efficacy and safety of risankizumab in adult patients with moderately to severely active Crohn's disease, involving 289 patients, of whom 65% had previously failed advanced therapies, indicating significant market demand for the drug.
- Diverse Treatment Options: If approved, patients will have the choice to receive SKYRIZI induction via subcutaneous injection or IV infusion, followed by subcutaneous maintenance dosing every eight weeks, which will likely improve patient adherence and treatment outcomes due to increased flexibility.
- Broad Impact of Crohn's Disease: Crohn's disease affects approximately 1 million Americans, causing significant physical and emotional burdens; AbbVie is committed to enhancing treatment standards through innovative research, reflecting the company's ongoing investment and dedication in the field of immunology.
See More
